Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2003

View Archived Issues

Interim results for rAAT in otitis media

GSK researchers describe new Lp-PLA2 inhibitors and their use in atherosclerosis therapy

Heterocyclic PPAR agonists under study at Novartis

Schering AG claims new antiandrogen agents for prostate cancer and other uses

Bayer scientists discover novel alpha7 nAChR agonists with utility in cognition deficits

Azole compounds for diabetes, cancer and lipoprotein disorders claimed by Maxia

New series of chemokine CCR3 receptor modulators identified at BMS

Morphochem presents new tryptase and uPA inhibitors

Factor Xa inhibitors prepared and tested by Aventis researchers

Statistically significant imbalance in adverse events in Hemolink trial

Positive phase I results for EOquin support initiation of phase II testing

GSK and Pozen to develop and commercialize novel migraine treatment

Phase III program under way for once-weekly idraparinux

EMEA expands Zometa labeling

Dendreon's phase III trial will serve as basis for Provenge approval

FDA approval for Stalevo

Positive phase III topline results for Alprox-TD

Niaspan receives U.K. approval

Glucose- and triglyceride-lowering effects of a novel pan-PPAR agonist in ZDF rats

DRF-4832 improves hyperglycemia, hyperlipidemia, hypertension and atherosclerosis in animal models

Preclinical and clinical efficacy of MK-767, a dual PPARalpha/PPARgamma agonist

Preclinical activity of LY-519818, a PPARgamma-dominant agonist

Inhibition of glycogen phosphorylase/hepatic glycogenolysis as an approach to type 2 diabetes

Spotlight on melatonin

Long-term efficacy and safety results reported for lanthanum carbonate in chronic renal failure

Interferon alfa variants with enhanced immunomodulatory and antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...